Nurosene (CSE: MEND) released some promising news last week to aid share prices on a push past resistance at $.745.
On January 17, $MEND announced that it has launched NetraPacebo, an AI-based technology solution designed to have an impact on clinical trial success rates in the US$94B central nervous system (CNS) therapeutics market.
With an overall probability of success in CNS trials of only 15%, NetraPlacebo is well-placed to help prevent clinical trial failure and minimize risk for pharmaceutical company's drug development programs prior to entering into expensive and time-consuming Phase 3 clinical trials.
As shares continue to rally from all-time lows, I expect more announcements in this vein to supply strong catalysts going forward.
$MEND shares have managed to gain 48% since January 25 and are currently priced at $.75. The company has a current valuation of $30.1 million.
https://ceo.ca/@newswire/nurosene-launches-netraplacebo-an-innovative-ai-technology